Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
143.3
USD
|
-0.28%
|
|
-0.76%
|
-25.13%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,840
|
15,100
|
20,282
|
29,238
|
24,021
|
18,122
|
-
|
-
|
Enterprise Value (EV)
1 |
12,293
|
13,417
|
18,522
|
28,132
|
23,979
|
17,782
|
17,523
|
17,217
|
P/E ratio
|
-14.2
x
|
-17.4
x
|
-23.6
x
|
-25.6
x
|
-54.4
x
|
-35
x
|
-81.8
x
|
72.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
58.4
x
|
30.6
x
|
24
x
|
28.2
x
|
13.1
x
|
9.78
x
|
7.99
x
|
5.88
x
|
EV / Revenue
|
55.9
x
|
27.2
x
|
21.9
x
|
27.1
x
|
13.1
x
|
9.6
x
|
7.72
x
|
5.59
x
|
EV / EBITDA
|
-13.9
x
|
-16.9
x
|
-28
x
|
-38
x
|
-
|
-49
x
|
-1,216
x
|
21.7
x
|
EV / FCF
|
-29.4
x
|
-19.6
x
|
-25.8
x
|
-45.9
x
|
572
x
|
-76.2
x
|
-635
x
|
25.6
x
|
FCF Yield
|
-3.41%
|
-5.11%
|
-3.88%
|
-2.18%
|
0.17%
|
-1.31%
|
-0.16%
|
3.91%
|
Price to Book
|
8.98
x
|
14.9
x
|
34.6
x
|
-186
x
|
-109
x
|
5,732
x
|
-176
x
|
50.9
x
|
Nbr of stocks (in thousands)
|
111,490
|
116,181
|
119,601
|
123,028
|
125,493
|
126,452
|
-
|
-
|
Reference price
2 |
115.2
|
130.0
|
169.6
|
237.6
|
191.4
|
143.3
|
143.3
|
143.3
|
Announcement Date
|
06/02/20
|
11/02/21
|
10/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
219.8
|
492.9
|
844.3
|
1,037
|
1,828
|
1,853
|
2,269
|
3,079
|
EBITDA
1 |
-885.1
|
-793.7
|
-661.1
|
-740.6
|
-
|
-363.2
|
-14.41
|
793.2
|
EBIT
1 |
-939.4
|
-828.4
|
-708.7
|
-785.1
|
-282.2
|
-414.5
|
-171
|
351.3
|
Operating Margin
|
-427.5%
|
-168.09%
|
-83.93%
|
-75.68%
|
-15.43%
|
-22.36%
|
-7.53%
|
11.41%
|
Earnings before Tax (EBT)
1 |
-885.3
|
-855.6
|
-852.1
|
-1,127
|
-433.5
|
-500
|
-240.9
|
275.7
|
Net income
1 |
-886.1
|
-858.3
|
-852.8
|
-1,131
|
-440.2
|
-514.7
|
-242.9
|
257.1
|
Net margin
|
-403.24%
|
-174.15%
|
-101.01%
|
-109.04%
|
-24.08%
|
-27.77%
|
-10.7%
|
8.35%
|
EPS
2 |
-8.110
|
-7.460
|
-7.200
|
-9.300
|
-3.520
|
-4.100
|
-1.751
|
1.980
|
Free Cash Flow
1 |
-418.6
|
-685.3
|
-718.1
|
-613.3
|
41.94
|
-233.5
|
-27.59
|
672.5
|
FCF margin
|
-190.48%
|
-139.05%
|
-85.05%
|
-59.12%
|
2.29%
|
-12.6%
|
-1.22%
|
21.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
84.78%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
261.55%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/02/20
|
11/02/21
|
10/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
187.6
|
258.5
|
213.3
|
224.8
|
264.3
|
335
|
319.3
|
318.8
|
750.5
|
439.7
|
426.9
|
461.4
|
464.1
|
487.7
|
504.8
|
EBITDA
1 |
-169.9
|
-183.2
|
-137.3
|
-181.6
|
-247.4
|
-174.3
|
-135.7
|
-216.7
|
227.2
|
-
|
-123.4
|
-110.4
|
-75.4
|
-52.6
|
-
|
EBIT
1 |
-181.7
|
-194.6
|
-146.7
|
-191.7
|
-258
|
-188.6
|
-149.8
|
-229.8
|
213.9
|
-116.4
|
-117.5
|
-97.75
|
-113.3
|
-106
|
-110.9
|
Operating Margin
|
-96.83%
|
-75.26%
|
-68.8%
|
-85.26%
|
-97.63%
|
-56.3%
|
-46.92%
|
-72.1%
|
28.5%
|
-26.47%
|
-27.53%
|
-21.19%
|
-24.42%
|
-21.74%
|
-21.97%
|
Earnings before Tax (EBT)
1 |
-204.2
|
-260.3
|
-239.4
|
-274.7
|
-405.9
|
-207
|
-172.4
|
-274.2
|
150.7
|
-137.7
|
-133.2
|
-114.3
|
-132.5
|
-124.3
|
-128.1
|
Net income
1 |
-204.5
|
-258.5
|
-240.3
|
-277.4
|
-405.9
|
-207.5
|
-174.1
|
-276
|
147.8
|
-137.9
|
-143.8
|
-127.1
|
-139.6
|
-121
|
-129.2
|
Net margin
|
-109%
|
-99.97%
|
-112.7%
|
-123.39%
|
-153.58%
|
-61.93%
|
-54.53%
|
-86.59%
|
19.69%
|
-31.35%
|
-33.68%
|
-27.54%
|
-30.07%
|
-24.8%
|
-25.59%
|
EPS
2 |
-1.720
|
-2.160
|
-2.000
|
-2.290
|
-3.320
|
-1.680
|
-1.400
|
-2.210
|
1.180
|
-1.100
|
-1.166
|
-1.039
|
-1.100
|
-0.9669
|
-0.9947
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/10/21
|
10/02/22
|
28/04/22
|
28/07/22
|
27/10/22
|
23/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
15/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
547
|
1,683
|
1,760
|
1,105
|
41.4
|
340
|
599
|
905
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-419
|
-685
|
-718
|
-613
|
41.9
|
-234
|
-27.6
|
673
|
ROE (net income / shareholders' equity)
|
-53.4%
|
-69.9%
|
-106%
|
-526%
|
-
|
-287%
|
-29.3%
|
68.8%
|
ROA (Net income/ Total Assets)
|
-44.6%
|
-29.6%
|
-24.2%
|
-31.5%
|
-11.9%
|
-7.99%
|
-3.01%
|
5.2%
|
Assets
1 |
1,985
|
2,901
|
3,525
|
3,595
|
3,688
|
6,443
|
8,063
|
4,945
|
Book Value Per Share
2 |
12.80
|
8.730
|
4.890
|
-1.280
|
-1.750
|
0.0300
|
-0.8200
|
2.820
|
Cash Flow per Share
2 |
-
|
-5.350
|
-5.420
|
-4.450
|
0.8300
|
-0.7500
|
2.600
|
5.910
|
Capex
1 |
140
|
70.4
|
76.4
|
72.1
|
62.2
|
88.4
|
97.5
|
120
|
Capex / Sales
|
63.78%
|
14.28%
|
9.05%
|
6.95%
|
3.4%
|
4.77%
|
4.3%
|
3.91%
|
Announcement Date
|
06/02/20
|
11/02/21
|
10/02/22
|
23/02/23
|
15/02/24
|
-
|
-
|
-
|
Last Close Price
143.3
USD Average target price
219.9
USD Spread / Average Target +53.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.13% | 18.12B | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B | | -16.98% | 10.07B |
Other Biotechnology & Medical Research
|